Cempra (CEMP) Sinks 14% Following FDA CRL on Solithromycin
Tweet Send to a Friend
Cempra, Inc. (Nasdaq: CEMP) is down 13.9% in pre-open trade Thursday ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
